Taro Pharmaceutical Industries Ltd reports results for the quarter ended in March - Earnings Summary

Taro Pharmaceutical Industries

20/05/2024 23:24

* Taro Pharmaceutical Industries Ltd  TARO.N  reported
quarterly
adjusted earnings of 40 cents​​ per share for the quarter ended
in March, higher than the same quarter last year, when the
company reported EPS of 18 cents.  The lone analyst forecast for
the quarter was for earnings of 31 cents per share. 
    * Revenue rose 12.5% to $164.94 million from a year ago;
analysts
expected $156.06 million. 
    * Taro Pharmaceutical Industries Ltd's reported EPS for the
quarter was 40 cents​.
    * The company reported quarterly net income of $15.08
million.
    * Taro Pharmaceutical Industries Ltd shares had fallen
by 0.1%
this quarter and gained 1.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Taro
Pharmaceutical Industries Ltd is $43.00 
This summary was machine generated from LSEG data May 20 at
10:24 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      0.31           0.40           Beat
 Dec. 31 2023      0.30           0.54           Beat
 Sep. 30 2023      0.18           0.38           Beat
 Jun. 30 2023      0.31           0.40           Beat